So many people keep asking me about Continue. What is it? What are you up to? Here you go... Continue started as a research effort two years ago, with the belief that if the human body is a system, it should also have its leverage points. The simple levers that, when adjusted, could fundamentally alter how we age and live. Along with a team of initially skeptical researchers, we've been investigating a penny-drop insight about human aging. Something that's been hiding in plain sight for eternity. But more on that in a few weeks. We are at the tail-end of the research on this hypothesis, which if true, could fundamentally change our understanding of biology and aging. But today isn't about that. It's bigger than that. Today, we are expanding Continue Research to include a $25 million fund (entirely personally backed) to support researchers across the world who dare to ask simpler questions than anyone else. Who believe biology might be far simpler than we've made it. For over a decade, I have believed that most of the world’s problems stem from our short human lifespans. Continue Research’s goal is to extend healthy human function long enough that humans stop making short-term decisions. Read more about Continue’s purpose at – continue.com This will be a multi-decadal journey. Our goal here is to become a small catalyst in humanity's journey of conscious evolution. To lead us into the Post-Darwin era. Researchers, please look us up and apply for funding/grants at – continue.com/researchers ——— PS: Continue is not a part of Eternal

When do machine learning models actually outperform standard polygenic scores? 🤔 In our new preprint, we benchmark how non-additive genetic effects (i.e, dominance deviations) shape polygenic prediction across simulated and UK Biobank traits. 👉 medrxiv.org/content/10.1101/… 🧵 1/6

🚨 The preprint for our GWAS of Alzheimer’s disease (AD) is out Preprint: medrxiv.org/content/10.1101/… 🧵

Many drug targets in ongoing Parkinson's disease clinical trials have strong genetic links. We prioritized PD GWAS genes that may represent our next-best candidates for developing disease-modifying therapeutics. rdcu.be/eh1gW

I'm so happy to share that our paper "Immune-developmental processes contribute to schizophrenia risk: insights from a genetic overlap study with height" has been published in Biological Psychiatry 🥳 biologicalpsychiatryjournal.…